Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Mithra Pharmaceuticals SA
MITRAMithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium. Address: Rue Saint-Georges 5, Liège, Belgium, 4000
Analytics
Preço Alvo de Wall Street
0.74 EURRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave MITRA
Análise de Dividendos MITRA
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos MITRA
Avaliação de ações MITRA
Relatório MITRA
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |